ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Artemisinin Attenuates Amyloid-Induced Brain Inflammation and Memory Impairments by Modulating TLR4/NF-κB Signaling

Zhao, Xia; Huang, Xiaosu; Yang, Chao; Jiang, Yizhou; Zhou, Wenshu; Zheng, Wenhua*广东药学院
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES2022-6DOI: 10.3390/ijms23116354
13被引9阅读
引用收藏
分享

摘要

The abnormal immune response is an early change in the pathogenesis of Alzheimer's disease (AD). Microglial activation is a crucial regulator of the immune response, which contributes to progressive neuronal injury by releasing neurotoxic products. Therefore, finding effective drugs to regulate microglial homeostasis and neuroinflammation has become a new AD treatment strategy. Artemisinin has potent anti-inflammatory and immune activities. However, it is unclear whether Artemisinin contributes to the regulation of microglial activation, thereby improving AD pathology. This study found that Artemisinin significantly reduced amyloid beta-peptide 1-42 (A beta(1-42))-induced increases in nitric oxide and reactive oxygen species and inflammatory factors in BV2 cells. In addition, Artemisinin inhibited the migration of microglia and prevented the expansion of the inflammatory cascade. The mechanical studies showed Artemisinin inhibited neuroinflammation and exerted neuroprotective effects by regulating the Toll-like receptor 4 (TLR4)/Nuclear factor-kappa B (NF-kappa B) signaling pathway. Similar results were obtained in AD model mice, in which Artemisinin administration attenuated A beta(1-42)-induced neuroinflammation and neuronal injury, reversing spatial learning and memory deficits. The anti-inflammatory effect of Artemisinin is also accompanied by the activation of the TLR4/NF-kappa B signaling pathway in the animal model. Our results indicate that Artemisinin attenuated A beta(1-42)-induced neuroinflammation and neuronal injury by stimulating the TLR4/NF-kappa B signaling pathway. These findings suggest that Artemisinin is a potential therapeutic agent for AD.

学科与关键词

关键词
Alzheimer's diseaseArtemisininneuroinflammationmicrogliacognitive disorder
相关
加载中…
  • Trilobatin Alleviates Cognitive Deficits and Pathologies in an Alzheimer's Disease Mouse Model
    Ding, Jiuyang; Huang, Jian; Yin, Dan; Liu, Ting; Ren, Zheng; Hu, Shanshan; Ye, Yuanliang; Le, Cuiyun; Zhao, Na; Zhou, Hongmei; Li, Zhu; Qi, Xiaolan; Huang, JiangOxidative Medicine and Cellular Longevity, 2021, 2021: 3298400.被引 8
  • Triptolide improves Alzheimer's disease by regulating the NF-κB signaling pathway through the lncRNA NEAT1/microRNA 361-3p/TRAF2 axis
    Zhou, Li*; Huang, Xuming; Li, Haiyan; Wang, Jihui; Lu, ZhengqiExperimental and Therapeutic Medicine, 2023, 26(3): 440.被引 1
  • The Multifunctional Anti-inflammatory Drugs Used in the Therapy of Alzheimer's Disease
    Shi, S.; Wang, Z.; Qiao, Z.*Current Medicinal Chemistry, 2013, 20(20): 2583-2588.被引 15
查看全部 →

发表信息

论文状态
公开发表
期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
发表日期
2022-06
卷期
第 23 卷, 第 11 期
页码
6354
DOI
10.3390/ijms23116354
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [31771128, 32070969]; Science and Technology Development Fund, Macau SAR [0127/2019/A3, 0044/2019/AGJ, 0113/2018/A3]; University of Macau [MYRG2018-00134-FHS, MYRG2020-00158-FHS]

作者

  • Z

    Zhao, Xia (第一作者)

  • H

    Huang, Xiaosu

    guangdong pharmaceut univ

查看全部 6 位作者收起作者
  • Y

    Yang, Chao

  • J

    Jiang, Yizhou

  • Z

    Zhou, Wenshu

  • Z

    Zheng, Wenhua (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417